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Abstract Metastatic breast cancer is currently incurable
and the goals of therapy focus on prolonging survival and
maintaining quality of life by controlling symptoms and
minimizing toxicity. Treatments for metastatic breast can-
cer include chemotherapeutic agents from various classes,
such as taxanes, vinca alkaloids, anthracyclines and anti-
metabolites. This review provides an overview of chemo-
therapeutic agents for the treatment of metastatic breast
cancer patients previously treated with anthracyclines and
taxanes, focusing on a clinical evaluation of eribulin, the
most recently approved agent for the treatment of meta-
static breast cancer. Eribulin is a synthetic derivative of
halichondrin B, a tumour growth inhibitor found in marine
sponges, which prevents microtubule growth and seques-
ters the tubulin molecules into unusual aggregates, initiat-
ing apoptosis. Studies of eribulin have shown that the drug
is effective in the treatment of previously treated metastatic
breast cancer, and has an acceptable toxicity profile.
Importantly, in the phase III EMBRACE study, eribulin
treatment resulted in a survival advantage, a difficult end-
point to achieve with a single chemotherapeutic agent. An
additional phase III study showed that eribulin has similar
efficacy to capecitabine in women treated with no more
than three prior therapies. Furthermore, pre-specified
exploratory analyses suggest that particular patient sub-
groups may have greater therapeutic benefit with eribulin
and may warrant further study to explore the potential
mechanisms.
1 Introduction
Breast cancer is the most common cancer in women. In 2008,
1.38 million new cases of breast cancer were diagnosed
worldwide, and there were over 458,000 deaths [1]. Over the
last 25 years, the incidence of breast-cancer related deaths
has declined in the USA and parts of Europe, mostly owing to
improved detection and treatment [2]. However, survival in
patients with breast cancer depends heavily on the stage of
the tumour, with US statistics demonstrating a 98 % survival
rate at 5 years in patients with non-invasive disease, such as
ductal carcinoma in situ, which decreases to 24 % in patients
with metastatic disease [3]. Unfortunately, approximately
one-third of women with early-stage breast cancer will
eventually develop metastatic disease [4], and metastatic
breast cancer is currently incurable.
The goals of therapy in patients who have metastatic
disease focus on prolonging survival and maintaining
quality of life by controlling symptoms and minimizing
toxicity. Treatment choice in breast cancer is influenced by
the hormone receptor and human epidermal growth factor
receptor 2 (HER2) status of the tumour, and patients with
metastatic disease may benefit from treatment tailored to
their individual genotype status. Several targeted therapies
are under development, but systemic chemotherapy
remains an important approach for patients with metastatic
breast cancer, particularly in patients with hormone-
refractory, hormone receptor-negative or rapidly pro-
gressing metastatic disease [4, 5].
This review provides an overview of chemotherapeutic
agents for the treatment of metastatic breast cancer patients
previously treated with anthracyclines and taxanes, focus-
ing on a clinical evaluation of eribulin, the most recently
approved agent for the treatment of metastatic breast
cancer.
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2 Chemotherapeutic Agents for Metastatic Breast
Cancer
Breast cancer can be treated with chemotherapeutic agents
from various classes, including antimicrotubule agents such
as taxanes and eribulin, anthracyclines and antimetabolites
[6–9]. Taxanes and anthracyclines are commonly used for
first-line treatment of breast cancer, but development of
drug resistance to these agents upon tumour recurrence is
common. Despite the high level of resistance in recurrent
breast cancer, studies have shown that third-line treatments
can extend the time of disease control in a significant
number of patients [10]. Agents used for treatment of
women with metastatic breast cancer who have been pre-
viously treated with anthracyclines and taxanes include
eribulin, ixabepilone and capecitabine (Table 1) [11–13].
Whereas antimicrotubule agents such as taxanes and
eribulin all act by sending the cell into apoptosis via
mitotic arrest after tubulin binding, the mechanism of
action of eribulin is unique amongst the antimicrotubule
agents [14, 15]. Whereas paclitaxel inhibits microtubule
shortening [14], eribulin prevents microtubule growth [15].
Eribulin binds to the plus ends of the microtubule [16],
inhibiting microtubule dynamics by suppressing microtu-
bule polymerization [15]. This in turn sequesters tubulin
into non-functional aggregates [15].
Anthracyclines such as doxorubicin and epirubicin
induce DNA intercalation and apoptosis of tumour cells
[17]. Antimetabolites, which include capecitabine and
gemcitabine, inhibit processes required for DNA synthesis
[11, 18] and the oral 5-fluorouracil (5-FU) analogue S-1 (a
combination of the prodrug tegafur and two modulators of
5-FU) acts following its biotransformation to cytotoxic
nucleotides [19]. Other choices for breast cancer treatment
include platinum analogues such as carboplatin and cis-
platin, which induce DNA adduct formation [20], and iri-
notecan, which inhibits DNA synthesis via an interaction
with topoisomerase I [21].
Several factors to be considered when selecting agents for
patients previously treated with anthracyclines and taxanes
include pre-treatment history, previous response, residual
toxicity and tumour aggressiveness. The standard regimen
for metastatic breast cancer patients previously treated with
anthracyclines and taxanes remains to be established.
3 Clinical and Pharmacological Evaluation of Eribulin
3.1 Pharmacological Properties
Eribulin is a synthetic derivative of halichondrin B, a cell-
cycle progression inhibitor found in marine sponges [15].
Eribulin was approved for the treatment of metastatic
breast cancer patients previously treated with anthracy-
clines and taxanes in the USA in 2010 [22] and in Europe
and Japan in 2011 [23, 24].
Phase I studies show that eribulin exhibits linear phar-
macokinetics. In patients with advanced solid tumours, the
peak drug plasma concentration was 44–528 ng/mL after
single doses of eribulin of 0.25–4.0 mg/m2 [25]. Eribulin
does not accumulate after multiple doses and is rapidly and
extensively distributed [25]. In a phase I study of eribulin in
patients with advanced solid tumours, the mean half-life
was 46.5 h [25]. A similarly prolonged half-life was seen in
a dose-ranging study of eribulin in Japanese patients with
refractory solid tumours (36.4–59.9 h with doses of
0.7–2.0 mg/m2 (Table 2) [26]. Eribulin exhibited triphasic
pharmacokinetics with a long terminal half-life, high vol-
ume of distribution and low urinary clearance. This study
was conducted to investigate higher doses of eribulin and to
determine the dose-limiting toxicities (DLT), the recom-
mended dose and the maximum tolerated dose in Japanese
patients. As expected, the pharmacokinetic parameters of
Cmax and area under the drug concentration–time curve
(AUC) of eribulin increased with each dose level (Table 2),
and an increase in dose correlated with the incidence of
Table 1 Chemotherapeutic agents for metastatic breast cancer: mechanism of action [11–13, 17–21]
Drug class Agents Mechanism of action
Anthracyclines Doxorubicin, epirubicin DNA intercalation and induction of cell death
Antimetabolites Capecitabine, S-1, gemcitabine Inhibits processes required for DNA synthesis
Antimicrotubule agents Paclitaxel Stabilizes microtubules by inhibiting the shortening of microtubules
Docetaxel
Ixabepilone
Eribulin Inhibits microtubules by suppressing microtubule growth at the plus end
Vinorelbine Inhibits microtubules by inhibiting the polymerization of tubulin dimers
and depolymerization
Platinum analogues Carboplatin, cisplatin Induces DNA adduct formation and cell death
Topoisomerase inhibitor Irinotecan Interferes with DNA coiling to inhibit transcription and replication
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adverse events [26]. This phase I study established the
recommended dose of 1.4 mg/m2. Maximum tolerated dose
(MTD) was 2.0 mg/m2 and the main DLT was neutropenia,
which was smoothly recovered and manageable. These
observations suggest that eribulin-related adverse events
can be managed by the appropriate dose modifications. On
the basis of this study and others to be discussed below,
dose delay or dose reduction to 1.1 and 0.7 mg/m2 is rec-
ommended upon the incidence of severe adverse events.
3.2 Clinical Properties
3.2.1 Phase II Studies
In phase II studies, eribulin exhibited efficacy in patients
with metastatic breast cancer who had previously been
heavily treated with other chemotherapeutic agents. Two
open-label, single-arm studies investigated the efficacy and
tolerability of eribulin in 103 and 291 patients with meta-
static breast cancer previously treated with an anthracy-
cline and a taxane (study 201; NCT00097721) [27] or an
anthracycline, taxane and capecitabine (study 211;
NCT00246090) [28], respectively. In the per-protocol
population of the smaller study (n = 87), eribulin had an
overall response rate of 11.5 %, whereas patients in the
larger study had an overall response rate of 9.3 %; in both
studies, all responses were considered partial [27, 28]. In
the smaller study, the clinical benefit rate, which includes
patients demonstrating a response and those with stable
disease for more than 6 months, was 17.2 % [27]. Patients
had a median progression-free survival of 2.6 months in
both studies, and median overall survival was 9.0 months
[27] and 10.4 months [28] (Table 3).
In Japanese patients with metastatic breast cancer pre-
viously treated with an anthracycline and a taxane (study
221) [29], eribulin appears to have a better efficacy than
that observed in the others mentioned in Table 3. This
open-label study of 80 patients who received 1.4 mg/m2 of
eribulin demonstrated that eribulin had an objective clinical
response rate of 21.3 % and a clinical benefit rate of
27.5 % in this patient population. However, this improved
efficacy may be in part due to patient characteristics. In the
previous two studies, patients had received a median of
four previous regimens of chemotherapy containing an
anthracycline plus a taxane and an anthracycline, taxane
and capecitabine combination, respectively. In study 221,
patients had received a median of three previous regimens
of chemotherapy containing an anthracycline and a taxane.
When the objective response rate was assessed according
to the number of previous chemotherapy regimens in the
metastatic setting, a higher response rate of 36 % was
observed in patients who had no or one previous regimen,
and patients who had a median of two or more previous
regimens had a decrease in response. In addition, further
investigation is needed to evaluate whether pharmacoge-
netic variation contributes to eribulin efficacy and safety,
because P-glycoprotein (P-gp) may be involved in eribulin
disposition and polymorphism of MDR1, the gene encod-
ing P-gp, affects chemotherapeutic outcome.
3.2.2 Phase III Studies
Two phase III studies have investigated the efficacy of
eribulin in metastatic breast cancer. EMBRACE (study
305; NCT00388726) compared eribulin with the physi-
cian’s choice of therapy in 762 patients, and another study
compared eribulin with capecitabine in 1,102 women pre-
viously treated with no more than three regimens (study
301; NCT00337103) [30, 31].
The encouraging results of the three phase II trials dis-
cussed previously led to the initiation of the phase III
EMBRACE study—a randomized, open-label, multinational
Table 2 Pharmacokinetic parameters and dose-limiting toxicities in the phase I study of eribulin in Japanese patients with advanced solid
tumours [26]
Eribulin dose
0.7 mg/m2 (n = 3) 1.0 mg/m2 (n = 3) 1.4 mg/m2 (n = 6) 2.0 mg/m2 (n = 3)
Cmax, ng/mL 288.5 ± 43.0 380.6 ± 52.9 519.4 ± 107.2 717.6 ± 104.3
AUC0–?, ngh/mL 299.2 ± 124.5 379.6 ± 65.2 672.7 ± 113.7 1,370.1 ± 282.2
t1/2, h 36.4 ± 11.2 42.9 ± 10.9 39.4 ± 8.3 59.9 ± 13.4
DLTa, n (%) 0 0 2 (33)b 3 (50)c
All data provided as mean ± standard deviation unless otherwise stated
AUC0–? area under the drug concentration–time curve from time 0 to infinity, DLT dose-limiting toxicities, Cmax peak drug concentration,
h hours, n number, t1/2 terminal half-life
a Assessed in cycle 1 of eribulin treatment
b Grade 4 neutropenia and grade 3 febrile neutropenia resulting in omission of the day 8 dose
c Grade 4 neutropenia, grade 3 neutropenia and grade 3 febrile neutropenia resulting in omission of the day 8 dose
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study that investigated the efficacy of eribulin in heavily pre-
treated women with locally recurrent or metastatic breast
cancer [30]. Patients were required to have previously
received between two and five chemotherapy regimens
including an anthracycline and a taxane, and two or more
regimens for locally recurrent or metastatic breast cancer. A
dosage of 1.4 mg/m2 of eribulin was administered intrave-
nously over 2–5 min on days 1 and 8 of a 21-day treatment
cycle, and patients in the treatment of physician’s choice
(TPC) group received single-agent chemotherapy, cancer
treatment-approved biological treatment, hormonal therapy,
radiotherapy or symptomatic treatment [30]. The proposed
TPC was chosen for each patient and confirmed before
central randomization. In the TPC arm, 96 % received
chemotherapy including vinorelbine, gemcitabine and
capecitabine, 4 % received hormonal therapy but no patient
received supportive care alone. The primary endpoint of the
EMBRACE study was overall survival.
Eribulin significantly increased the median overall sur-
vival of patients compared with the TPC group (13.1 vs
10.6 months; hazard ratio [HR] 0.81, 95 % confidence
interval [CI] 0.66, 0.99; p = 0.041; Table 4). In the erib-
ulin treatment group there were 274 deaths (54 %) com-
pared with 148 (58 %) in the TPC group; corresponding
1-year survival rates were 53.9 and 43.7 %, respectively
[30]. The median progression-free survival (assessed by
investigator review) was also significantly prolonged with
eribulin treatment (HR 0.76; 95 % CI 0.64, 0.90;
p = 0.002; Table 4); however, when assessed by inde-
pendent review the difference in progression-free survival
no longer appeared significant (HR 0.87; 95 % CI 0.71,
1.05; p = 0.137; Table 4).
In patients with measurable disease, significantly more
patients had an objective response (assessed by indepen-
dent review) in the eribulin treatment group (12 %) com-
pared with the TPC group (5 %; p = 0.002) (Table 4). The
Table 3 Phase II studies of eribulin in patients with metastatic breast cancer who have previously received an anthracycline and taxane
201 [27] 211 [28] 221 [29]
n 103 291 80
Prior chemotherapy Any prior regimen of chemotherapy
with A and T (median 4)
2–5 prior regimens of chemotherapy
with A, T and CAP (median 4)
B3 prior regimens of chemotherapy
including A and T (median 3)
Dosing schedule 1.4 mg/m2 IV inf
d1 ? 8 ? 15 q4w
1.4 mg/m2 IV inf d1 ? 8
q3w
1.4 mg/m2 IV inf d1 ? 8
q3w
1.4 mg/m2 IV inf d1 ? 8
q3w
Tumour response



















Median PFS (months) 2.6 2.6 3.7
Median OS (months) 9.0 10.4 11.1
A anthracycline, CAP capecitabine, CBR clinical benefit rate, d day, IV inf intravenous infusion, ORR objective response rate, OS overall
survival, PFS progression-free survival, PR partial response, qXw every X weeks, SD stable disease, T taxane
a Objective response rate = complete response ? partial response
b Clinical benefit rate = complete response ? partial response ? stable disease C6 months
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clinical benefit rates were 23 % (95 % CI 18.9, 26.7) for
eribulin and 17 % (12.1, 22.5) in the TPC group.
On the basis of the demonstration of a statistically sig-
nificant prolongation of overall survival, eribulin mesylate
was approved by the US Food and Drug Administration
(FDA). This approval highlights the appropriate use of an
innovative trial design and shows that improvement in
overall survival is an achievable endpoint in the setting of
advanced breast cancer.
Study 301 was a phase III, randomized, open-label,
multinational study that also investigated the efficacy of
eribulin in heavily pre-treated women with locally recur-
rent or metastatic breast cancer [31]. Patients were required
to have previously received at most three chemotherapy
regimens (at most two for advanced disease) with each
regimen including an anthracycline or a taxane. Patients
were randomized to either 1.4 mg/m2 of eribulin (admin-
istered intravenously over 2–5 min on days 1 and 8 of a
21-day treatment cycle) or oral capecitabine (1,250 mg/m2
twice daily on days 1–14 of a 21-day treatment cycle) [31].
The co-primary endpoints of study 301 were overall sur-
vival and progression-free survival.
Like the EMBRACE study, eribulin increased the
median overall survival of patients compared with cape-
citabine (15.9 vs 14.5 months; HR 0.88, 95 % CI 0.77,
1.00; p = 0.056; Table 4), although this difference was not
statistically significant. In contrast, the median progres-
sion-free survival of both arms was almost identical
(assessed by independent review) (Table 4). Similarly, in
patients with measurable disease, there was no apparent
difference in the proportion of patients who had an
objective response rate (assessed by independent review) in
the eribulin treatment group (11 %) compared with cape-
citabine (12 %) (Table 4).
Pre-specified exploratory analyses of the phase III trials
discussed here suggest that particular patient subgroups may
have greater therapeutic benefit with eribulin (Table 5). In
particular, patients who are HER2 negative, oestrogen
receptor negative or triple negative had significantly longer
overall survival rates with eribulin treatment compared with
capecitabine in study 301, as presented at the 2012 San
Antonio Breast Cancer Symposium (Table 5) [31, 32].
However, although overall survival was prolonged in certain
subgroups of patients receiving eribulin in study 301, the
objective response rate and progression-free survival were
similar between eribulin and capecitabine treatment in all
subgroups assessed. This may be due to several factors: (1)
patients receiving eribulin were allowed to cross over to
capecitabine, whereas patients receiving capecitabine were
allowed to receive eribulin less frequently, owing to the
limited market access prior to approval; (2) more patients
receiving eribulin may maintain better quality of life and
accept a subsequent chemotherapy regimen owing to its
lower toxicity; or (3) eribulin might have a promoting effect
on the clinical activity of the subsequent chemotherapy
regimen through the alteration of tumour phenotype,
although this possibility is currently just speculation. Further
basic research and clinical investigations focusing on these
ideas are warranted to determine the possible cause of the
increase in overall survival with eribulin.
Table 4 Phase III studies of eribulin in patients with metastatic breast cancer who have previously received an anthracycline and taxane
305 (EMBRACE) [30] 301 [31]
Eribulin TPC Eribulin CAP
n 508 254 554 548













Median PFS, months 3.7 3.6 2.2 2.2 4.1 4.2
Tumour response (%)
CR 1 \1 0 0 NR NR
PR 12 13 5 7 NR NR
SD 44 47 45 45 NR NR
ORRa 12§ 13} 5 7 11 12
CBRb 23 28 17 20 NR NR
CAP capecitabine, CBR clinical benefit rate, CR complete response, NR not reported in meeting abstract, ORR objective response rate, OS overall
survival, PFS progression-free survival, PR partial response, SD stable disease, TPC treatment of physician’s choice
* p = 0.041 vs TPC;  p = 0.056 vs CAP;  p = 0.002 vs TPC; § p = 0.002 vs TPC; } p = 0.028 vs TPC
a Objective response rate = complete response ? partial response
b Clinical benefit rate = complete response ? partial response ? stable disease C6 months
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3.3 Tolerability
Phase I studies have suggested that eribulin doses of
1.0–2.0 mg/m2 result in a manageable toxicity profile, and
as a result the approved dosage of eribulin is a 2–5 min
infusion of 1.4 mg/m2 on days 1 and 8 of a cycle lasting
21 days [12, 25, 26, 33]. Eribulin continued to exhibit an
acceptable toxicity profile in both phase II [27–29] and
phase III [30, 31] studies.
Consistent with the findings of the phase II trials [27–
29], in the EMBRACE trial adverse events were reported in
497 (99 %) patients receiving eribulin and 230 (93 %)
patients receiving the TPC; of these, 126 (25 %) and 64
(26 %) patients reported serious adverse events [30]. The
most common adverse events in either treatment group
were asthenia or fatigue (54 and 40 % of patients receiving
eribulin and the TPC, respectively) and neutropenia (52
and 30 %, respectively). More patients receiving eribulin
reported grade 3 or 4 neutropenia (45 vs 21 %), leukopenia
(14 vs 6 %) or peripheral neuropathy (8 vs 2 %) [30].
Peripheral neuropathy was the most common adverse
event leading to discontinuation of eribulin in the
EMBRACE trial, with 24 (5 %) patients discontinuing
treatment [30]. However, the incidence of peripheral neu-
ropathy was similar in the eribulin treatment group (over-
all, 35 % of patients; grade 3, 8 %; grade 4,\1 %) and the
taxane (overall, 45 % of patients; grade 3, 5 %; no grade 4)
treatment group [30].
Similarly, the adverse events reported in study 301 were
consistent with the previously known side effects of erib-
ulin [31]. Adverse events were reported in 94.1 % of
patients receiving eribulin and 90.5 % of patients receiving
capecitabine; 17.5 and 21.1 % of patients reported serious
adverse events [31]. More patients receiving eribulin had
neutropenia (54 vs 16 %) and leukopenia (31 vs 10 %);
however, the incidence of anaemia, thrombocytopenia and
febrile neutropenia was similar between treatment groups
[31]. Other common adverse events reported in patients
receiving eribulin included alopecia (35 %), nausea
(22 %), fatigue (17 %) and asthenia (15 %). Peripheral
sensory neuropathy was observed in 13 % of patients
(grade 3, 4 % of patients; no grade 4) [31].
4 Ongoing Studies of Eribulin and Other Agents
There are several ongoing studies investigating eribulin in
breast cancer, including those investigating eribulin in the
neo-adjuvant [34–38] and adjuvant setting [39–41], in
patients with metastatic disease [42–49], and in combina-
tion with other anti-cancer agents [34, 37–40, 42, 43, 45–
49] (Table 6).
So far, preliminary results of three studies of eribulin
have been presented and suggest that eribulin would be
efficacious and well tolerated as a treatment in other breast
cancer populations. Preliminary results of two ongoing
clinical trials that are investigating eribulin as first-line
therapy either as monotherapy (NCT01268150) [50] or
combination therapy (NCT01269346) [51] were presented
at the 2012 San Antonio Breast Cancer Symposium. These
results showed that as first-line therapy for patients with
locally recurrent or metastatic breast cancer, eribulin
appears to have anti-tumour activity and an acceptable
safety profile, both when given as monotherapy and in
combination with trastuzumab [50, 51].
The treatment of early-stage breast cancer with eribulin
is also being investigated (NCT01328249) and preliminary
results of this trial were presented at the 2012 San Antonio
Breast Cancer Symposium [52]. This study, which is
investigating the efficacy and safety of adjuvant eribulin in
patients with early-stage breast cancer who have received
dose-dense doxorubicin and cyclophosphamide, suggests
that eribulin has an acceptable safety profile in this patient
group.
Table 5 Subgroup analysis of overall survival in the phase III studies of eribulin by human epidermal growth factor receptor 2 (HER2) and
oestrogen receptor (ER) status
305 (EMBRACE) [30] 301 [31, 32]
OS (months) HR (95 % CI) OS (months) HR (95 % CI)
Eribulin TPC Eribulin CAP
Total 13.2 10.5 0.81 (0.66, 0.99) 15.9 14.5 0.88 (0.77, 1.00)
HER2? 11.3 9.1 0.76 (0.47, 1.24) 14.3 17.1 0.97 (0.69, 1.36)
HER2- 13.2 10.5 0.81 (0.64, 1.02) 15.9 13.5 0.84 (0.72, 0.98)
ER? 13.8 11.4 0.81 (0.63, 1.04) 18.2 16.8 0.90 (0.74, 1.09)
ER- 10.2 7.8 0.78 (0.54, 1.13) 14.4 10.5 0.78 (0.64, 0.96)
TN 9.5 7.0 0.71 (0.46, 1.10) 14.4 9.4 0.70 (0.55, 0.91)
CAP capecitabine, ER oestrogen receptor, HER2 human epidermal growth factor receptor 2, TN triple negative, TPC treatment of physician’s
choice
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In addition to eribulin, several novel cytotoxic chemo-
therapies have been evaluated in clinical trials (Table 7)
and encouraging results have been reported [53, 54]. Tra-
ditional taxanes have large, complex molecular structures
with hydrophobic and water-insoluble properties which
require the drug be prepared with a toxic solvent, limiting
the drug’s clinical use. Therefore, many clinical studies
investigating novel solvent-free formulations are ongoing.
Novel solvent-free taxane formulations include nanoparti-
cle albumin-bound (nab)–paclitaxel, cationic liposomal
paclitaxel (EndoTAG-1) and paclitaxel poliglumex (pac-
litaxel bound to a biodegradable poly-L-glutamic acid)
(reviewed by Villanueva et al. [54]). Nab–paclitaxel is
already available for breast cancer and is taking the place
of solvent-based paclitaxel. Novel taxanes including la-
rotaxel, tesetaxel and cabazitaxel and novel non-taxanes
Table 6 Ongoing clinical studies investigating eribulin in patients with breast cancer
Study design Treatments Study identifier





Neo-adjuvant HER2? Phase I/II, OL,
SG (56)
pCR Eribulin ? carboplatin, trastuzumab NCT01388647 [34]
HER2- Phase II, OL, SG
(47)
pCR Eribulin then dose-dense doxorubicin ?
cyclophosphamide
NCT01498588 [35]
HER2- Phase II, R, PG,
OL (152)
pCR Eribulin then FAC vs paclitaxel then FEC NCT01593020 [36]
HER2- Phase II, R, PG,
OL (76)
pCR Eribulin ? cyclophosphamide vs
docetaxel ? cyclophosphamide
NCT01527487 [37]
TN Phase II, SG, OL
(30)
pCR Eribulin ? carboplatin NCT01372579 [38]
Adjuvant TN, HER2?,
HER2-
Phase II, PG, OL
(148)
2-year DFS Eribulin or eribulin ? trastuzumab in
patients who do not achieve pCR
following neo-adjuvant chemotherapy
NCT01401959 [39]
ER? Phase II, SG, OL
(67)
Feasibility Eribulin ? capecitabine NCT01439282 [40]
NS Phase II, SG, OL
(80)
Feasibility Dose-dense




First-line HER2? Phase II, SG, OL
(52)
ORR Eribulin ? trastuzumab NCT01269346 [42]
First-line HER2- Phase II, SG, OL
(52)
ORR Eribulin NCT01268150 [44]
Second-line HER2- Phase II, R, PG,
OL (141)
PFS Eribulin ?/- ramucirumab NCT01427933 [45]
Second-line TN Phase I/II SG,
OL (80)
MTD, PFS Eribulin ? PLX 3397 NCT01596751 [46]




Eribulin ? capecitabine NCT01323530 [47]




Eribulin ? lapatinib NCT01534455 [43]
NS NS Phase I/II, SG,
OL (58)
MTD, CBR Eribulin ? cyclophosphamide NCT01554371 [48]





Eribulin ? sorafenib NCT01585870 [49]
AUC area under the drug concentration–time curve, CBR clinical benefit rate, Cmax peak drug concentration, DFS disease-free survival, ER
oestrogen receptor, FAC fluorouracil ? doxorubicin ? cyclophosphamide, FEC fluorouracil ? epirubicin ? cyclophosphamide, HER2 human
epidermal growth factor receptor 2, MTD maximum tolerated dose, NS not specified, OL open label, ORR objective response rate, pCR
pathological complete response rate, PFS progression-free survival, PG parallel group, R randomized, SG single group, TN triple negative, TTP
time to progression
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such as vinflunine and indibulin are being evaluated in
phase II or III trials [54]. In contrast to other antimi-
crotubule agents, tesetaxel is orally active and is not a
substrate for P-gp [54], and therefore may generate a new
paradigm for breast cancer treatment. New agents of other
classes are also in clinical development [53]; these include
liposomal doxorubicin, the antimetabolite pemetrexed, the
platinum analogue satraplatin and the irinotecan prodrug
NKTR-102.
5 Conclusions
Because metastatic breast cancer remains incurable with
currently available systemic therapies, novel approaches
are crucial. Studies of eribulin have shown that the drug is
effective in the treatment of previously treated metastatic
breast cancer, and has an acceptable toxicity profile.
Importantly, in the phase III EMBRACE study, eribulin
treatment resulted in a survival advantage, a difficult end-
point to achieve with a single chemotherapeutic agent. An
additional phase III study showed that eribulin has similar
efficacy to capecitabine in women treated with no more
than three prior therapies. Furthermore, pre-specified
exploratory analyses suggest that particular patient sub-
groups may have greater therapeutic benefit with eribulin,
and may warrant further study to explore the potential
mechanisms behind these differences.
In addition, several classes of new cytotoxic chemother-
apeutic agents are currently being evaluated in clinical trials
and these promising agents may offer solutions to the diffi-
cult issues surrounding breast cancer. Considering the high
efficacy of taxanes in breast cancer, new antimicrotubule
agents including eribulin are expected to achieve the primary
goals of systemic therapy, which are to prolong survival and
improve quality of life, thereby realizing the wish of patients
with an incurable disease to live longer and better.
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